Anika Therapeutics, Inc. (ANIK) Tops Q3 EPS by 7c

Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q3 EPS of $0.40, $0.07 better than the analyst estimate of $0.33. Revenue for the quarter came in at $22.1 million versus the consensus estimate of $20.33 million.

For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• RenovoRx regains Nasdaq minimum bid price compliance
• Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'